Literature DB >> 32944395

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.

Min Liu1, Qian Sun1, Feng Wei1, Xiubao Ren1.   

Abstract

The programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) signaling pathway is an important mechanism in tumor immune escape, and expression of PD-L1 on tumor cells has been reported more frequently. However, accumulating evidence suggests that PD-1/PD-L1 is also widely expressed on immune cells, and that regulation is also critical for tumor immune responses. In this review, we emphasized that under solid tumor conditions, the immunoregulatory effects of immune cells expressing PD-1 or PD-L1, affected the prognoses of cancer patients. Therefore, a better understanding of the mechanisms that regulate PD-1 or PD-L1 expression on immune cells would provide clear insights into the increased efficacy of anti-PD antibodies and the development of novel tumor immunotherapy strategies. Copyright:
© 2020, Cancer Biology & Medicine.

Entities:  

Keywords:  Immune cell; immunotherapy; programmed cell death ligand 1; programmed cell death-1; solid tumor

Year:  2020        PMID: 32944395      PMCID: PMC7476099          DOI: 10.20892/j.issn.2095-3941.2020.0112

Source DB:  PubMed          Journal:  Cancer Biol Med        ISSN: 2095-3941            Impact factor:   4.248


  86 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

2.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

Authors:  Joy Hsu; Jonathan J Hodgins; Malvika Marathe; Chris J Nicolai; Marie-Claude Bourgeois-Daigneault; Troy N Trevino; Camillia S Azimi; Amit K Scheer; Haley E Randolph; Thornton W Thompson; Lily Zhang; Alexandre Iannello; Nikhita Mathur; Karen E Jardine; Georgia A Kirn; John C Bell; Michael W McBurney; David H Raulet; Michele Ardolino
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

3.  PD-L1+ regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis.

Authors:  Hao Wu; Liming Xia; Dongdong Jia; Hanhui Zou; Gu Jin; Wenkang Qian; Haichao Xu; Tao Li
Journal:  Mol Immunol       Date:  2020-01-27       Impact factor: 4.407

4.  Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.

Authors:  Catalina Lee-Chang; Aida Rashidi; Jason Miska; Peng Zhang; Katarzyna C Pituch; David Hou; Ting Xiao; Mariafausta Fischietti; Seong Jae Kang; Christina L Appin; Craig Horbinski; Leonidas C Platanias; Aurora Lopez-Rosas; Yu Han; Irina V Balyasnikova; Maciej S Lesniak
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

5.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Authors:  Don M Benson; Courtney E Bakan; Anjali Mishra; Craig C Hofmeister; Yvonne Efebera; Brian Becknell; Robert A Baiocchi; Jianying Zhang; Jianhua Yu; Megan K Smith; Carli N Greenfield; Pierluigi Porcu; Steven M Devine; Rinat Rotem-Yehudar; Gerard Lozanski; John C Byrd; Michael A Caligiuri
Journal:  Blood       Date:  2010-05-11       Impact factor: 22.113

6.  Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.

Authors:  Viktor Fleming; Xiaoying Hu; Céline Weller; Rebekka Weber; Christopher Groth; Zeno Riester; Laura Hüser; Qian Sun; Vasyl Nagibin; Carsten Kirschning; Vincenzo Bronte; Jochen Utikal; Peter Altevogt; Viktor Umansky
Journal:  Cancer Res       Date:  2019-07-23       Impact factor: 12.701

Review 7.  The PD-1 pathway in tolerance and autoimmunity.

Authors:  Loise M Francisco; Peter T Sage; Arlene H Sharpe
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

8.  Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.

Authors:  Orin Bloch; Courtney A Crane; Rajwant Kaur; Michael Safaee; Martin J Rutkowski; Andrew T Parsa
Journal:  Clin Cancer Res       Date:  2013-04-23       Impact factor: 12.531

9.  Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.

Authors:  Shabnam Shalapour; Xue-Jia Lin; Ingmar N Bastian; John Brain; Alastair D Burt; Alexander A Aksenov; Alison F Vrbanac; Weihua Li; Andres Perkins; Takaji Matsutani; Zhenyu Zhong; Debanjan Dhar; Jose A Navas-Molina; Jun Xu; Rohit Loomba; Michael Downes; Ruth T Yu; Ronald M Evans; Pieter C Dorrestein; Rob Knight; Christopher Benner; Quentin M Anstee; Michael Karin
Journal:  Nature       Date:  2017-11-08       Impact factor: 49.962

10.  PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors:  Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more
  1 in total

Review 1.  Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review.

Authors:  Jinhan Zhou; Qinghua Mao; Yining Li; Zhiyong Li; Hong He; Qianming Chen; Chuanxia Liu
Journal:  BMC Oral Health       Date:  2021-11-02       Impact factor: 2.757

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.